# US 2010/0196875 A1 · Human erythrovirus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0196875 A1
- Document ID: US20100196875A1
- Status: Published application
- Kind: A1
- Application number: 12/523,309
- Filed: 2008-01-15
- Published: 2010-08-05
- Earliest claimed: 2007-01-16
- Assignees: Talecris Biotherapeutics, Inc.
- Inventors: Douglas C. Lee; Todd M. Gieman; Chris Glenn; Burton Beams; Brett Buno; Lori Rinckel
- Web page: https://patentgrep.com/patent/US20100196875A1

## CPC

- C12Q 1/701: {Specific hybridization probes}
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 2750/14221: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Nucleic acid molecules derived from sequences of novel human parvovirus B19 variant genomes are provided. Also provided are assays and kits comprising the nucleic acid molecules.

## Claims

### Claim 1

An isolated nucleic acid molecule comprising a nucleotide sequence as set forth in SEQ ID NO: 1, SEQ ID NO:128, SEQ ID NO:129, or a complement thereof.

### Claim 2

An isolated nucleic acid molecule comprising a sequence consisting of at least 12, at least 15, or at least 20 contiguous nucleotides, wherein the contiguous nucleotides are a nucleotide sequence, or a complement thereof, selected from the group consisting of:
(SEQ ID NO: 2)
5′-GATAACTGGTGGTGCTCT-3′;
(SEQ ID NO: 3)
5′-ACTTCTGACTGGGA-3′;
(SEQ ID NO: 4)
5′-GAATGTAACAAATTTGA-3′;
(SEQ ID NO: 5)
5′-TTATTTAATAATGT-3′;
(SEQ ID NO: 6)
5′-CTTGTAACTGAAA-3′;
(SEQ ID NO: 7)
5′-TTTAGAGATGGAGA-3′;
(SEQ ID NO: 8)
5′-TTAATGAAAAAAAT-3′;
(SEQ ID NO: 9)
5′-CCTTTAAATGTTGT-3′;
(SEQ ID NO: 10)
5′-CAGACTTTGAGCAGG-3′;
(SEQ ID NO: 11)
5′-TGGAATAATGAAAA-3′;
(SEQ ID NO: 12)
5′-TTTCCATTTAATGATGTAGC-3′;
(SEQ ID NO: 13)
5′-TTGGTGGTCTGGGATGA-3′;
(SEQ ID NO: 14)
5′-GAAGCTGCAAAAGCCATTTTAGG-3′;
(SEQ ID NO: 15)
5′-ACCAGGGTAGATCA-3′;
(SEQ ID NO: 16)
5′-ATAACCAGCAATGGTGACATTAC-3′;
(SEQ ID NO: 17)
5′-CATGCTAAAGCCTTAAA-3′;
(SEQ ID NO: 18)
5′-AGCCCTGACATGGG-3′;
(SEQ ID NO: 19)
5′-TGGTGTAATGCACAAAGCTGG-3′;
(SEQ ID NO: 20)
5′-CCACTATGAAAACTGGGCAATAAACTACAC-3′;
(SEQ ID NO: 21)
5′-TTTGATTTCCCTGGAAT-3′;
(SEQ ID NO: 22)
5′-AATGCAGATGCCCTCCACCCAGA-3′;
(SEQ ID NO: 23)
5′-CTCCAAACCACCCC-3′;
(SEQ ID NO: 24)
5′-TCAGCAGCAGTGGTGGTGAAAGCTCTGAAGAACTC-3′;
(SEQ ID NO: 25)
5′-CCAGGCGCCTGGAACA-3′;
(SEQ ID NO: 26)
5′-TGAAACCCCGCGCTCTAGTACGCC-3′;
(SEQ ID NO: 27)
5′-TCCCCGGGACCAGTTCAGGAGAATCATTTGTCGGAAGC-3′;
(SEQ ID NO: 28)
5′-CAGTTTCGTGAACTGTTAGT-3′;
(SEQ ID NO: 29)
5′-GCTTGGTATAATGGATGGAA-3′;
(SEQ ID NO: 30)
5′-AAATGTGCTTACCT-3′;
(SEQ ID NO: 31)
5′-TTTGTAGATTATGAGTAAA-3′;
(SEQ ID NO: 32)
5′-ATTTCTTTAGATAATCC-3′;
(SEQ ID NO: 33)
5′-TATATAGTCATCATTTTCA-3′;
(SEQ ID NO: 34)
5′-CATGGACAGTTATCTGACCACCCCCATGCCTTATCATCCAGTA-3′;
(SEQ ID NO: 35)
5′-CAGAACCTAGAGGAGAAAATGCAGTATTATCTA-3′;
(SEQ ID NO: 36)
5′-TGAAGACTTACACAAGCCTGGGCAAGTTAGC-3′;
(SEQ ID NO: 37)
5′-TACCCGGTACTAACTATGTTGGGCCTGGCAATGAG-3′;
(SEQ ID NO: 38)
5′-TACAAGCTGGGCC-3′;
(SEQ ID NO: 39)
5′-GACAGTGCTGCAAGGATTCATGACTTTAGGTATAGCCAA-3′;
(SEQ ID NO: 40)
5′-TTAAAAAATATAAAAAATGAAAC-3′;
(SEQ ID NO: 41)
5′-TACTTTACTTTAAAAGGTGCAGCTGCCCCTGTGGCCCATTTTCAAGG
AAGTTT-3′;
(SEQ ID NO: 42)
5′-TACAACGCCTCAGAAAAATACCC-3′;
(SEQ ID NO: 43)
5′-AGCATGACTTCAGTTAA-3′;
(SEQ ID NO: 44)
5′-TCTGCAGAAGCCAGCACTGGTGCAGG-3′;
(SEQ ID NO: 45)
5′-AAAAGCATGTGGAGTGA-3′;
(SEQ ID NO: 46)
5′-AGTAGCTGCCACAATGC-3′;
(SEQ ID NO: 47)
5′-TTAGATTTTAATGCTTT-3′;
(SEQ ID NO: 48)
5′-GATGCTTTAACTGT-3′;
(SEQ ID NO: 49)
5′-TATGCTTACTTAACAGTAGG-3′;
(SEQ ID NO: 50)
5′-AGTGAAGAATCAGC-3′;
(SEQ ID NO: 51)
5′-TTTTATGAAATGTACAA-3′;
(SEQ ID NO: 52)
5′-GCTGAAGACAAAGAGTATCA-3′;
(SEQ ID NO: 53)
5′-AATGAAAAAGAACA-3′;
(SEQ ID NO: 54)
5′-TGGAACAGAAGAGC-3′;
(SEQ ID NO: 55)
5′-CTTCACTATGAAAG-3′;
(SEQ ID NO: 56)
5′-CCTCAAATATTTTTAAAAATA-3′;
(SEQ ID NO: 57)
5′-CCTCAAATATTTTTAAAAATA-3′;
(SEQ ID NO: 58)
5′-CATTTACCATATGTACT-3′;
(SEQ ID NO: 59)
5′-TATGACCCCACAGCTACAGATGCAAA-3′;
(SEQ ID NO: 60)
5′-GGATATGAAAAGCCTGAAGAATTGTGGAC-3′;
(SEQ ID NO: 134)
5′-TCAGCAGCAGTGGTGGTGAAAGCTCTGAAGAACTCAGTGAAAGCAGC
TTT-3′;
and
(SEQ ID NO: 135)
5′-CTTAAAAACTCTCCAGAC-3′.

### Claim 3

An isolated nucleic acid molecule comprising a sequence consisting of at least 12, at least 15, or at least 20 contiguous nucleotides, wherein the contiguous nucleotides are a nucleotide sequence, or a complement thereof, selected from the group consisting of:
(SEQ ID NO: 13)
5′-TTGGTGGTCTGGGATGA-3′;
(SEQ ID NO: 14)
5′-GAAGCTGCAAAAGCCATTTTAGG-3′;
(SEQ ID NO: 15)
5′-ACCAGGGTAGATCA-3′;
(SEQ ID NO: 16)
5′-ATAACCAGCAATGGTGACATTAC-3′;
(SEQ ID NO: 17)
5′-CATGCTAAAGCCTTAAA-3′;
(SEQ ID NO: 18)
5′-AGCCCTGACATGGG-3′;
(SEQ ID NO: 19)
5′-TGGTGTAATGCACAAAGCTGG-3′;
(SEQ ID NO: 20)
5′-CCACTATGAAAACTGGGCAATAAACTACAC-3′;
(SEQ ID NO: 21)
5′-TTTGATTTCCCTGGAAT-3′;
(SEQ ID NO: 22)
5′-AATGCAGATGCCCTCCACCCAGA-3′;
(SEQ ID NO: 23)
CTCCAAACCACCCC-3′;
(SEQ ID NO: 24)
5′-TCAGCAGCAGTGGTGGTGAAAGCTCTGAAGAACTC-3′;
(SEQ ID NO: 25)
5′-CCAGGCGCCTGGAACA-3′;
(SEQ ID NO: 26)
5′-TGAAACCCCGCGCTCTAGTACGCC-3′;
(SEQ ID NO: 27)
5′-TCCCCGGGACCAGTTCAGGAGAATCATTTGTCGGAAGC-3′;
(SEQ ID NO: 28)
5′-CAGTTTCGTGAACTGTTAGT-3′;
(SEQ ID NO: 29)
5′-GCTTGGTATAATGGATGGAA-3′;
(SEQ ID NO: 30)
5′-AAATGTGCTTACCT-3′;
(SEQ ID NO: 31)
5′-TTTGTAGATTATGAGTAAA-3′;
(SEQ ID NO: 32)
5′-ATTTCTTTAGATAATCC-3′;
(SEQ ID NO: 33)
5′-TATATAGTCATCATTTTCA-3′;
(SEQ ID NO: 34)
5′-CATGGACAGTTATCTGACCACCCCCATGCCTTATCATCCAGTA-3′;
(SEQ ID NO: 35)
5′-CAGAACCTAGAGGAGAAAATGCAGTATTATCTA-3′;
(SEQ ID NO: 36)
5′-TGAAGACTTACACAAGCCTGGGCAAGTTAGC-3′;
(SEQ ID NO: 37)
5′-TACCCGGTACTAACTATGTTGGGCCTGGCAATGAG-3′;
(SEQ ID NO: 38)
5′-TACAAGCTGGGCC-3′;
(SEQ ID NO: 134)
5′-TCAGCAGCAGTGGTGGTGAAAGCTCTGAAGAACTCAGTGAAAGCAGC
TTT-3′;
and
(SEQ ID NO: 135)
5′-CTTAAAAACTCTCCAGAC-3′.

### Claim 4

An isolated nucleic acid molecule comprising a sequence consisting of at least 12, at least 15, or at least 20 contiguous nucleotides, wherein the contiguous nucleotides are a nucleotide sequence, or a complement thereof, selected from the group consisting of:
(SEQ ID NO: 13)
5′-TTGGTGGTCTGGGATGA-3′;
(SEQ ID NO: 17)
5′-CATGCTAAAGCCTTAAA-3′;
(SEQ ID NO: 18)
5′-AGCCCTGACATGGG-3′;
(SEQ ID NO: 19)
5′-TGGTGTAATGCACAAAGCTGG-3′;
(SEQ ID NO: 22)
5′-AATGCAGATGCCCTCCACCCAGA-3′;
(SEQ ID NO: 24)
5′-TCAGCAGCAGTGGTGGTGAAAGCTCTGAAGAACTC-3′;
(SEQ ID NO: 25)
5′-CCAGGCGCCTGGAACA-3′;
(SEQ ID NO: 27)
5′-TCCCCGGGACCAGTTCAGGAGAATCATTTGTCGGAAGC-3′;
(SEQ ID NO: 31)
5′-TTTGTAGATTATGAGTAAA-3′;
(SEQ ID NO: 35)
5′-CAGAACCTAGAGGAGAAAATGCAGTATTATCTA-3′;
(SEQ ID NO: 36)
5′-TGAAGACTTACACAAGCCTGGGCAAGTTAGC-3′;
and
(SEQ ID NO: 134)
5′-TCAGCAGCAGTGGTGGTGAAAGCTCTGAAGAACTCAGTGAAAGCAGC
TTT-3′.

### Claim 5

An isolated nucleic acid molecule comprising at least 12, at least 15, or at least 20 contiguous nucleotides of a nucleotide sequence or a complement thereof, wherein the contiguous nucleotides are contained in a nucleotide sequence, or a complement thereof, selected from the group consisting of:
(SEQ ID NO: 61)
5′-CACTTCTGACTGGGAACCATTAACTCATTCTAACAGACT-3′,
(SEQ ID NO: 62)
5′-ATGTAAAGCTTAAATTTTTACCAGGAATGACTACAAAAG-3′,
(SEQ ID NO: 63)
5′-AATATTTTAGAGATGGAGAACAATTTATAGAAAATTATT-3′,
(SEQ ID NO: 64)
5′-ATTTTAGAGATGGAGAACAATTTATAGAAAATTATTTAA-3′,
(SEQ ID NO: 65)
5′-TAACCAATATTGATGGGTACATAGATACCTGCATTTCTG-3′,
(SEQ ID NO: 66)
5′-ATGGGTACATAGATACCTGCATTTCTGCTTCTTTTAGAC-3′,
(SEQ ID NO: 67)
5′-TTAGACGGGGAGCCTTTCAGGCTAAAAAACCCCGCATTA-3′,
(SEQ ID NO: 68)
5′-GAACCAGGGGAATCTAGCGCTACAGGGGGAGATGTTGTG-3′,
(SEQ ID NO: 69)
5′-TGCCATTTGCTGGGAAGGGGACTAAAGCTGGAATAAAAT-3′,
(SEQ ID NO: 70)
5′-GGACTAAAGCTGGAATAAAATTTCAAACTATGGTAAATT-3′,
(SEQ ID NO: 71)
5′-TAAATTGGTTGTGTGAAAATAGGGTTTTTACAGAGGATA-3′,
(SEQ ID NO: 72)
5′-ATTGGTTGTGTGAAAATAGGGTTTTTACAGAGGATAAGT-3′,
(SEQ ID NO: 73)
5′-TTAACCAGTACACTTTACTTAGCAGTAGTCACAGTGGGA-3′,
(SEQ ID NO: 74)
5′-TAAAACTAGCTATTTATAAGGCTACCAATTTAGTGCCTA-3′,
(SEQ ID NO: 75)
5′-TAGCTATTTATAAGGCTACCAATTTAGTGCCTACAAGTA-3′,
(SEQ ID NO: 76)
5′-CTACCAATTTAGTGCCTACAAGTACATTTTTGTTACACA-3′,
(SEQ ID NO: 77)
5′-CAAGTACATTTTTGTTACACACAGACTTTGAGCAGGCTA-3′,
(SEQ ID NO: 78)
5′-CACACAGACTTTGAGCAGGCTAACTGTATTAAAGAAAAT-3′,
(SEQ ID NO: 79)
5′-GTGTCAAAATTATGACCCCTTGTTGGTGGGACAGCATGT-3′,
(SEQ ID NO: 80)
5′-GGATTGATAAAAAATGTGGCAAAAAAAATACACTGTGGT-3′,
(SEQ ID NO: 81)
5′-ATACACTGTGGTTTTATGGCCCACCAAGTACAGGAAAAA-3′,
(SEQ ID NO: 82)
5′-GTACAGGAAAAACAAATTTAGCAATGGCTATTGCTAAAA-3′,
(SEQ ID NO: 83)
5′-GCTTGGTGGTCTGGGATGAGGGTATTATTAAGTCTACTA-3′,
(SEQ ID NO: 84)
5′-GCTTACTTACAGAGGCTGACGTGCAGCAATGGCTTACAT-3′,
(SEQ ID NO: 85)
5′-CCCCGCGCTCTAGTACGCCAGTCCCCGGGACCAGTTCAG-3′,
(SEQ ID NO: 86)
5′-AGAATCATTTGTCGGAAGCTCAATTTCCTCCGAAGCTGT-3′,
(SEQ ID NO: 87)
5′-ATCATTTGTCGGAAGCTCAATTTCCTCCGAAGCTGTAGC-3′,
(SEQ ID NO: 88)
5′-AGCTCAATTTCCTCCGAAGCTGTAGCTGCATCGTGGGAA-3′,
(SEQ ID NO: 89)
5′-TGACTATGTATGGGATGGTATAAGGGGTTTACCTGTTTG-3′,
(SEQ ID NO: 90)
5′-TTAATAACAGTGGGGGAGGCTTGGGATTTTGTCCCCATT-3′,
(SEQ ID NO: 91)
5′-CAGTGGGGGAGGCTTGGGATTTTGTCCCCATTGCATTAA-3′,
(SEQ ID NO: 92)
5′-GCAAAAAATGTGCTTACCTATCTGGCTTGCAAAGTTTTG-3′,
(SEQ ID NO: 93)
5′-AATGTGCTTACCTATCTGGCTTGCAAAGTTTTGTAGATT-3′,
(SEQ ID NO: 94)
5′-TTTGTAGATTATGAGTAAAGAAATTGGTAAATGGTGGGA-3′,
(SEQ ID NO: 95)
5′-TTATGAGTAAAGAAATTGGTAAATGGTGGGAAAGTGATG-3′,
(SEQ ID NO: 96)
5′-CTTCTTTGTTTGACTTAGTGGCTCGTATTAAAAGTAACC-3′,
(SEQ ID NO: 97)
5′-ATGAAACTGGGTTTCAAGCTCAAGTAGTAAAAGACTACT-3′,
(SEQ ID NO: 98)
5′-TCCTGATGCTTTAACTGTTGCCATATCAGAAATTGCCAT-3′,
(SEQ ID NO: 99)
5′-TTGCCATATCAGAAATTGCCATTAAAGATGTTACAGACA-3′,
(SEQ ID NO: 100)
5′-TGCCATATCAGAAATTGCCATTAAAGATGTTACAGACAA-3′,
(SEQ ID NO: 101)
5′-AATACAAGTACCCATATGTATTAGGTCAAGGACAAGATA-3′,
(SEQ ID NO: 102)
5′-AAGATACCTTAGCCCCAGAGCTTCCAATTTGGGTGTACT-3′,
(SEQ ID NO: 103)
5′-CAGTAGGAGATGTAAACACGCAGGGAATTTCTGGGGACA-3′,
(SEQ ID NO: 104)
5′-AGAATCAGCGTTTTATGTCCTGGAACACAGCTCTTTTGA-3′,
(SEQ ID NO: 105)
5′-CTACTATGTCTTATAAGTTCCCTCCAGTGCCCCCAGAGA-3′,
(SEQ ID NO: 106)
5′-TCCCTCCAGTGCCCCCAGAGAATTTAGAAGGCTGTAGTC-3′,
(SEQ ID NO: 107)
5′-CCCGTTTAGGAGTCCCTGATACATTAGGAGGGGACCCCA-3′,
(SEQ ID NO: 108)
5′-AACACATGAAGACCACGCAGTTCAGCCACAAAATTTTAT-3′,
(SEQ ID NO: 109)
5′-ACGCAGTTCAGCCACAAAATTTTATGCCAGGGCCACTGG-3′,
(SEQ ID NO: 110)
5′-GGCCACTGGTAAACTCAGTTTCCACAAAGGAGGGAGACA-3′,
(SEQ ID NO: 111)
5′-AGGAGGGAGACAGTTCTAACACAGGAGCGGGAAAAGCCC-3′,
(SEQ ID NO: 112)
5′-GTCAAAGTACTAGAATATCATTACGCCCTGGTCCAGTGT-3′,
(SEQ ID NO: 113)
5′-GCCCTGGTCCAGTGTCTCAACCATATCACCACTGGGACA-3′,
(SEQ ID NO: 114)
5′-GTCCAGTGTCTCAACCATATCACCACTGGGACACAGATA-3′,
(SEQ ID NO: 115)
5′-CAGATAAATATGTAACAGGGATAAATGCCATTTCTCATG-3′,
(SEQ ID NO: 116)
5′-CTGAAGACAAAGAGTATCAACAGGGCGTGGGTAGGTTTC-3′,
(SEQ ID NO: 117)
5′-AAGACAAAGAGTATCAACAGGGCGTGGGTAGGTTTCCCA-3′,
(SEQ ID NO: 118)
5′-AGGGCGTGGGTAGGTTTCCCAATGAAAAAGAACAACTAA-3′,
(SEQ ID NO: 119)
5′-AACAGTTACAGGGTTTAAATATACACACATATTTTCCCA-3′,
(SEQ ID NO: 120)
5′-GTTTAAATATACACACATATTTTCCCAATAAAGGTACCC-3′,
(SEQ ID NO: 121)
5′-TACCAAATTTAGATGACAGCTTTAAAACTCAGTTTGCAG-3′,
(SEQ ID NO: 122)
5′-AGCTTTAGGAGGTTGGGGACTACATCAGCCACCCCCTCA-3′,
(SEQ ID NO: 123)
5′-GGCCAATTGGGGGTATTAAGTCAATGGGAATAACAACAT-3′,
(SEQ ID NO: 124)
5′-TTAAGTCAATGGGAATAACAACATTAGTTCAATATGCTG-3′,
(SEQ ID NO: 125)
5′-TAGTTCAATATGCTGTGGGTATTATGACAGTAACTATGA-3′,
(SEQ ID NO: 126)
5′-TAACTATGACATTTAAATTAGGGCCTCGCAAAGCTACAG-3′,
and
(SEQ ID NO: 127)
5′-ACCCTCCTCACGCAGCAGGCCATTTACCATATGTACTAT-3′.

### Claim 6

An isolated nucleic acid molecule consisting of a nucleotide sequence or a complement thereof, wherein the nucleotide sequence is selected from the group consisting of:
(SEQ ID NO: 136)
5′-TGAAACCCCGCGCTCTA-3′;
(SEQ ID NO: 137)
5′-AACTAACAGTTCACGAAACTG-3′;
(SEQ ID NO: 138)
5′-TCCCCGGGACCAGTTCAGGAGAA-3′;
(SEQ ID NO: 139)
5′-TCAGCAGCAGTGGTGGT-3′;
(SEQ ID NO: 140)
5′-TAGAGCGCGGGGTTTCA-3′;
(SEQ ID NO: 141)
5′-TGAAAGCTCTGAAGAACTCAGTGAAAGCAGCTTT-3′;
(SEQ ID NO: 142)
5′-AATGCAGATGCCCTCCAC-3′;
(SEQ ID NO: 143)
5′-TCAGCAGCAGTGGTGGTGAAAGCTCTGAA-3′;
(SEQ ID NO: 144)
5′-TGTTCCAGGCGCCTG-3′;
(SEQ ID NO: 145)
5′-CACAGCTACAGATGCAAA-3′;
(SEQ ID NO: 146)
5′-GGTGCACACGGCTTTT-3′;
(SEQ ID NO: 147)
5′-TGTCCACAATTCTTCAGGCTTTTCATATCC-3′;
(SEQ ID NO: 148)
5′-TGGATATGAAAAGCCTGAAGTATTGTGGAC-3′;
(SEQ ID NO: 149)
5′-GGTCATTTACCATATGTACT-3′;
(SEQ ID NO: 150)
5′-AGCTACAGATGCAAANCAACACCACAGACA-3′;
(SEQ ID NO: 151)
5′-GAAAACTTTCCATTTAATGATGT-3′;
(SEQ ID NO: 152)
5′-ATTTTTTGATCTACCCTGGT-3′;
(SEQ ID NO: 153)
5′-TTGGTGGTCTGGGATGAAGG-3′;
(SEQ ID NO: 154)
5′-GTTTTATGGGCCGCCAAGTA-3′;
(SEQ ID NO: 155)
5′-TTCATCCCAGACCACCAAGG-3′;
(SEQ ID NO: 156)
5′-ATGGCTATTGCTAAAACTGTTCCAGTGTA-3′;
(SEQ ID NO: 157)
5′-TGGAATAATGAAAACTTTCCATTTAATGATGTAG-3′;
and
(SEQ ID NO: 158)
5′-CAATGGCCATTGCTAAAAGTGTTCCA-3′.

### Claim 7

An isolated nucleic acid molecule that anneals under a stringent condition to a polynucleotide comprising a nucleotide sequence as set forth in SEQ ID NO: 1, SEQ ID NO:128, SEQ ID NO:129, or a complement thereof, but does not anneal under the stringent condition to a non-parvovirus B19 DNA or RNA molecules that may be present in a test sample.

### Claim 8

An isolated nucleic acid molecule that anneals under a stringent condition to a nucleotide sequence as set forth in SEQ ID NO: 1, SEQ ID NO:128, SEQ ID NO:129, or a complement thereof, wherein the isolated nucleic acid molecule also anneals under the stringent condition to a DNA or a RNA of parvovirus B19 Au, A6, V9, or D91.1.

### Claim 9

An isolated nucleic acid molecule that anneals under a stringent condition to a nucleotide sequence or a complement thereof, wherein the nucleotide sequence is as set forth in SEQ ID NO: 1, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, and SEQ ID NO:133.

### Claim 10

An isolated nucleic acid molecule that anneals under a stringent condition to a nucleotide sequence as set forth in SEQ ID NO: 1, SEQ ID NO:128, SEQ ID NO:129, or a complement thereof, wherein the isolated nucleic acid molecule does not anneal under the stringent condition to a DNA or a RNA of parvovirus B19 Au, A6, V9, or D91.1.

### Claim 11

An isolated nucleic acid molecule comprising an open reading frame, a partial open reading frame, wherein the open reading frame is comprised in SEQ ID NO: 1, SEQ ID NO:128, SEQ ID NO:129, or a complement thereof.

### Claim 12

An isolated human erythrovirus comprising a genome comprising a nucleotide sequence as set forth in SEQ ID NO: 1, SEQ ID NO:128, or SEQ ID NO:129.

### Claim 13

A kit comprising at least one primer and at least one probe, wherein the at least one primer comprises a primer nucleic acid sequence as set forth in (SEQ ID NO: 136), (SEQ ID NO: 137), (SEQ ID NO: 139), (SEQ ID NO: 140), (SEQ ID NO: 142), (SEQ ID NO: 144), (SEQ ID NO: 145), (SEQ ID NO: 146), (SEQ ID NO: 149), (SEQ ID NO: 151), (SEQ ID NO: 152), (SEQ ID NO: 154), or (SEQ ID NO: 155), wherein the at least one probe comprises a probe nucleic acid sequence as set forth in (SEQ ID NO: 138), (SEQ ID NO: 141), (SEQ ID NO: 143), (SEQ ID NO: 147), (SEQ ID NO: 148), (SEQ ID NO: 150), (SEQ ID NO: 153), (SEQ ID NO: 156), (SEQ ID NO: 157), (SEQ ID NO: 158), or complements thereof.

### Claim 14

A kit comprising a forward primer, a reverse primer, and a probe, wherein the forward primer comprises a forward primer nucleic acid sequence as set forth in (SEQ ID NO: 136), (SEQ ID NO: 139), (SEQ ID NO: 142), (SEQ ID NO: 145), (SEQ ID NO: 149), (SEQ ID NO: 151), or (SEQ ID NO: 154), wherein the reverse primer comprises a reverse primer nucleic acid sequence as set forth in (SEQ ID NO: 137), (SEQ ID NO: 140), (SEQ ID NO: 144), (SEQ ID NO: 146), (SEQ ID NO: 152), or (SEQ ID NO: 155), wherein the probe comprises a probe nucleic acid sequence as set forth in (SEQ ID NO: 136), (SEQ ID NO: 137), (SEQ ID NO: 138), (SEQ ID NO: 139), (SEQ ID NO: 140), (SEQ ID NO: 141), (SEQ ID NO: 142), (SEQ ID NO: 143), (SEQ ID NO: 144), (SEQ ID NO: 145), (SEQ ID NO: 146), (SEQ ID NO: 147), (SEQ ID NO: 148), (SEQ ID NO: 149), (SEQ ID NO: 150), (SEQ ID NO: 151), (SEQ ID NO: 152), (SEQ ID NO: 153), (SEQ ID NO: 154), (SEQ ID NO: 155), (SEQ ID NO: 156), (SEQ ID NO: 157), (SEQ ID NO: 158), or complements thereof.

### Claim 15

A method for detecting a parvovirus B19 in a sample, the method comprising:
a) performing PCR with at least a portion of the sample using a forward primer having a forward primer nucleic acid sequence and a reverse primer having a reverse primer nucleic acid sequence, wherein the forward primer nucleic acid sequence is as set forth in (SEQ ID NO: 136), (SEQ ID NO: 139), (SEQ ID NO: 142), (SEQ ID NO: 145), (SEQ ID NO: 149), (SEQ ID NO: 151), or (SEQ ID NO:154), wherein the reverse primer nucleic acid sequence is as set forth in (SEQ ID NO: 137), (SEQ ID NO: 140), (SEQ ID NO: 144), (SEQ ID NO: 146), (SEQ ID NO: 152), or (SEQ ID NO:155); and
b) determining the presence or absence of an amplicon, wherein the presence of the amplicon is indicative of the presence of the parvovirus B19 in the sample, wherein determining comprises annealing an oligonucleotide to the amplicon.

### Claim 16 (depends on 15)

The method of claim 15, wherein the oligonucleotide comprises a sequence as set forth in (SEQ ID NO: 138), (SEQ ID NO: 141), (SEQ ID NO: 143), (SEQ ID NO: 147), (SEQ ID NO: 148), (SEQ ID NO: 150), (SEQ ID NO: 153), (SEQ ID NO: 156), (SEQ ID NO: 157), (SEQ ID NO: 158), or complements thereof.

### Claim 17

A method for determining parvovirus B19 in a sample, the method comprising:
a) amplifying parvovirus B19 nucleic acid in the sample using at least one nucleic acid molecule comprising
i) a sequence consisting of at least 12, at least 15, or at least 20 contiguous nucleotides or a complement thereof, wherein the contiguous nucleotides are contained in a nucleotide sequence selected from the group consisting of (SEQ ID NO: 2), (SEQ ID NO: 3), (SEQ ID NO: 4), (SEQ ID NO: 5), (SEQ ID NO: 6), (SEQ ID NO: 7), (SEQ ID NO: 8), (SEQ ID NO: 9), (SEQ ID NO: 10), (SEQ ID NO: 11), (SEQ ID NO: 12), (SEQ ID NO: 13), (SEQ ID NO: 14), (SEQ ID NO: 15), (SEQ ID NO: 16), (SEQ ID NO: 17), (SEQ ID NO: 18), (SEQ ID NO: 19), (SEQ ID NO: 20), (SEQ ID NO: 21), (SEQ ID NO: 22), (SEQ ID NO: 23), (SEQ ID NO: 24), (SEQ ID NO: 25), (SEQ ID NO: 26), (SEQ ID NO: 27), (SEQ ID NO: 28), (SEQ ID NO: 29), (SEQ ID NO: 30), (SEQ ID NO: 31), (SEQ ID NO: 32), (SEQ ID NO: 33), (SEQ ID NO: 34), (SEQ ID NO: 35), (SEQ ID NO: 36), (SEQ ID NO: 37), (SEQ ID NO: 38), (SEQ ID NO: 39), (SEQ ID NO: 40), (SEQ ID NO: 41), (SEQ ID NO: 42), (SEQ ID NO: 43), (SEQ ID NO: 44), (SEQ ID NO: 45), (SEQ ID NO: 46), (SEQ ID NO: 47), (SEQ ID NO: 48), (SEQ ID NO: 49), (SEQ ID NO: 50), (SEQ ID NO: 51), (SEQ ID NO: 52), (SEQ ID NO: 53), (SEQ ID NO: 54), (SEQ ID NO: 55), (SEQ ID NO: 56), (SEQ ID NO: 57), (SEQ ID NO: 58), (SEQ ID NO: 59), and (SEQ ID NO: 60); or
ii) at least 12, at least 15, or at least 20 contiguous nucleotides of a nucleotide sequence or a complement thereof, wherein the nucleotide sequence is selected from the group consisting of: (SEQ ID NO: 61), (SEQ ID NO: 62), (SEQ ID NO: 63), (SEQ ID NO: 64), (SEQ ID NO: 65), (SEQ ID NO: 66), (SEQ ID NO: 67), (SEQ ID NO: 68), (SEQ ID NO: 69), (SEQ ID NO: 70), (SEQ ID NO: 71), (SEQ ID NO: 72), (SEQ ID NO: 73), (SEQ ID NO: 74), (SEQ ID NO: 75), (SEQ ID NO: 76), (SEQ ID NO: 77), (SEQ ID NO: 78), (SEQ ID NO: 79), (SEQ ID NO: 80), (SEQ ID NO: 81), (SEQ ID NO: 82), (SEQ ID NO: 83), (SEQ ID NO: 84), (SEQ ID NO: 85), (SEQ ID NO: 86), (SEQ ID NO: 87), (SEQ ID NO: 88), (SEQ ID NO: 89), (SEQ ID NO: 90), (SEQ ID NO: 91), (SEQ ID NO: 92), (SEQ ID NO: 93), (SEQ ID NO: 94), (SEQ ID NO: 95), (SEQ ID NO: 96), (SEQ ID NO: 97), (SEQ ID NO: 98), (SEQ ID NO: 99), (SEQ ID NO: 100), (SEQ ID NO: 101), (SEQ ID NO: 102), (SEQ ID NO: 103), (SEQ ID NO: 104), (SEQ ID NO: 105), (SEQ ID NO: 106), (SEQ ID NO: 107), (SEQ ID NO: 108), (SEQ ID NO: 109), (SEQ ID NO: 110), (SEQ ID NO: 111), (SEQ ID NO: 112), (SEQ ID NO: 113), (SEQ ID NO: 114), (SEQ ID NO: 115), (SEQ ID NO: 116), (SEQ ID NO: 117), (SEQ ID NO: 118), (SEQ ID NO: 119), (SEQ ID NO: 120), (SEQ ID NO: 121), (SEQ ID NO: 122), (SEQ ID NO: 123), (SEQ ID NO: 124), (SEQ ID NO: 125), (SEQ ID NO: 126), and (SEQ ID NO: 127); and
b) detecting an amplicon generated in step (a), wherein detection of the amplicon indicates presence of the variant in the sample, wherein detecting optionally comprises the step of annealing at least one nucleic acid molecule of step (a)(ii) to the amplicon.

### Claim 18

A method for determining parvovirus B19 in a sample, the method comprising:
a) amplifying parvovirus B19 nucleic acid in the sample using at least one nucleic acid molecule comprising a sequence consisting of at least 12, at least 15, or at least 20 contiguous nucleotides or a complement thereof, wherein the contiguous nucleotides are contained in a nucleotide sequence selected from the group consisting of: (SEQ ID NO: 2), (SEQ ID NO: 3), (SEQ ID NO: 4), (SEQ ID NO: 5), (SEQ ID NO: 6), (SEQ ID NO: 7), (SEQ ID NO: 8), (SEQ ID NO: 9), (SEQ ID NO: 10), (SEQ ID NO: 11), (SEQ ID NO: 12), (SEQ ID NO: 13), (SEQ ID NO: 14), (SEQ ID NO: 15), (SEQ ID NO: 16), (SEQ ID NO: 17), (SEQ ID NO: 18), (SEQ ID NO: 19), (SEQ ID NO: 20), (SEQ ID NO: 21), (SEQ ID NO: 22), (SEQ ID NO: 23), (SEQ ID NO: 24), (SEQ ID NO: 25), (SEQ ID NO: 26), (SEQ ID NO: 27), (SEQ ID NO: 28), (SEQ ID NO: 29), (SEQ ID NO: 30), (SEQ ID NO: 31), (SEQ ID NO: 32), (SEQ ID NO: 33), (SEQ ID NO: 34), (SEQ ID NO: 35), (SEQ ID NO: 36), (SEQ ID NO: 37), (SEQ ID NO: 38), (SEQ ID NO: 39), (SEQ ID NO: 40), (SEQ ID NO: 41), (SEQ ID NO: 42), (SEQ ID NO: 43), (SEQ ID NO: 44), (SEQ ID NO: 45), (SEQ ID NO: 46), (SEQ ID NO: 47), (SEQ ID NO: 48), (SEQ ID NO: 49), (SEQ ID NO: 50), (SEQ ID NO: 51), (SEQ ID NO: 52), (SEQ ID NO: 53), (SEQ ID NO: 54), (SEQ ID NO: 55), (SEQ ID NO: 56), (SEQ ID NO: 57), (SEQ ID NO: 58), (SEQ ID NO: 59), and (SEQ ID NO: 60); and
b) detecting an amplicon generated in step (a), wherein detection of the amplicon indicates presence of the parvovirus B19 in the sample, wherein detecting optionally comprises the step of annealing at least one nucleic acid molecule to the amplicon.